Overview
- Two pivotal B-Well studies met primary endpoints, with bepirovirsen plus standard care delivering a statistically significant, clinically meaningful functional cure rate over standard care alone.
- The companies did not disclose exact functional cure percentages, with full datasets slated for a scientific meeting and peer‑reviewed publication.
- More than 1,800 patients across 29 countries were enrolled, and the safety and tolerability profile was described as acceptable and consistent with earlier studies.
- Bepirovirsen is intended as a six‑month course that aims to suppress virus and surface antigen to undetectable levels, potentially enabling patients to avoid long‑term therapy.
- Analysts called the readout encouraging yet cautioned that adoption and labeling hinge on detailed data; GSK projects over £2 billion in peak sales as Ionis remains eligible for milestone payments and tiered royalties.